Literature DB >> 24325469

Evaluation of a cholecystokinin 2 receptor-targeted near-infrared dye for fluorescence-guided surgery of cancer.

Charity Wayua1, Philip S Low.   

Abstract

Surgical resection of malignant disease remains one of the most effective tools for treating cancer. Tumor-targeted near-infrared dyes have the potential to improve contrast between normal and malignant tissues, thereby enabling surgeons to more quantitatively resect malignant disease. Because the cholecystokinin 2 receptor (CCK2R and its tumor-specific splice variant CCK2i4svR) is overexpressed in cancers of the lungs, colon, thyroid, pancreas, and stomach, but absent or inaccessible to parenterally administered drugs in most normal tissues, we have undertaken to design a targeting ligand that can deliver attached near-infrared dyes to CCK2R+ tumors. We report here the synthesis and biological characterization of a CCK2R-targeted conjugate of the near-infrared dye, LS-288 (CRL-LS288). We demonstrate that CRL-LS288 binds selectively to CCK2R+ cancer cells with low nanomolar affinity (Kd = 7 × 10(-9) M). We further show that CRL-LS288 localizes primarily to CCK2R-expressing HEK 293 murine tumor xenografts and that dye uptake in these xenografts is significantly reduced when CCK2R are blocked by preinjection of excess ligand (CRL) or when mice are implanted with CCK2R-negative tumors. Because CRL-LS288 is also found to reveal the locations of distant tumor metastases, we suggest that CRL-LS288 has the potential to facilitate intraoperative identification of malignant disease during a variety of cancer debulking surgeries.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24325469     DOI: 10.1021/mp400429h

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  10 in total

1.  [99mTc]Tc-DGA1, a Promising CCK2R-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography.

Authors:  Aikaterini Kaloudi; Panagiotis Kanellopoulos; Thorsten Radolf; Oleg G Chepurny; Maritina Rouchota; George Loudos; Fritz Andreae; George G Holz; Berthold Artur Nock; Theodosia Maina
Journal:  Mol Pharm       Date:  2020-07-07       Impact factor: 4.939

Review 2.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents.

Authors:  Madduri Srinivasarao; Chris V Galliford; Philip S Low
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

3.  Design, Synthesis, and Evaluation of a Neurokinin-1 Receptor-Targeted Near-IR Dye for Fluorescence-Guided Surgery of Neuroendocrine Cancers.

Authors:  Ananda Kumar Kanduluru; Madduri Srinivasarao; Philip S Low
Journal:  Bioconjug Chem       Date:  2016-09-02       Impact factor: 4.774

4.  Evaluation of a Carbonic Anhydrase IX-Targeted Near-Infrared Dye for Fluorescence-Guided Surgery of Hypoxic Tumors.

Authors:  Peng-Cheng Lv; Jyoti Roy; Karson S Putt; Philip S Low
Journal:  Mol Pharm       Date:  2016-04-04       Impact factor: 4.939

Review 5.  Current and future intraoperative imaging strategies to increase radical resection rates in pancreatic cancer surgery.

Authors:  Henricus J M Handgraaf; Martin C Boonstra; Arian R Van Erkel; Bert A Bonsing; Hein Putter; Cornelis J H Van De Velde; Alexander L Vahrmeijer; J Sven D Mieog
Journal:  Biomed Res Int       Date:  2014-07-15       Impact factor: 3.411

6.  Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue.

Authors:  Jyoti Roy; Karson S Putt; Domenico Coppola; Marino E Leon; Farah K Khalil; Barbara A Centeno; Noel Clark; Valerie E Stark; David L Morse; Philip S Low
Journal:  Oncotarget       Date:  2016-03-22

7.  Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand.

Authors:  Charity Wayua; Jyoti Roy; Karson S Putt; Philip S Low
Journal:  Mol Pharm       Date:  2015-06-16       Impact factor: 4.939

8.  Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers.

Authors:  Jyoti Roy; Miranda Kaake; Philip S Low
Journal:  Oncotarget       Date:  2019-01-04

9.  Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting.

Authors:  Marco Verona; Sara Rubagotti; Stefania Croci; Sophia Sarpaki; Francesca Borgna; Marianna Tosato; Elisa Vettorato; Giovanni Marzaro; Francesca Mastrotto; Mattia Asti
Journal:  Molecules       Date:  2021-02-09       Impact factor: 4.411

10.  Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study.

Authors:  Berthold A Nock; Panagiotis Kanellopoulos; Oleg G Chepurny; Maritina Rouchota; George Loudos; George G Holz; Eric P Krenning; Theodosia Maina
Journal:  Pharmaceutics       Date:  2022-03-18       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.